Canada - English - Health Canada

homeocan inc. - scopolamine hydrobromide - tablet - 6ch - scopolamine hydrobromide 6ch - homeopathic products

Israel - English - Ministry of Health

teva pharmaceutical indust.ltd - scopolamine hydrobromide 0.25 mg/ml - solution for injection - scopolamine - scopolamine is used in cases where antimuscarinic action is desired, such as in premedication, where reduction of excitement and production of amnesia, in conjunction with morphine or pethidine, are desired.

Canada - English - Health Canada

pfizer canada ulc - scopolamine hydrobromide - solution - 0.4mg - scopolamine hydrobromide 0.4mg - antimuscarinics antispasmodics

Canada - English - Health Canada

pfizer canada ulc - scopolamine hydrobromide - solution - 0.6mg - scopolamine hydrobromide 0.6mg - antimuscarinics antispasmodics

Canada - English - Health Canada

omega laboratories limited - scopolamine hydrobromide - liquid - 0.4mg - scopolamine hydrobromide 0.4mg - antimuscarinics antispasmodics

Canada - English - Health Canada

omega laboratories limited - scopolamine hydrobromide - liquid - 0.6mg - scopolamine hydrobromide 0.6mg - antimuscarinics antispasmodics

United States - English - NLM (National Library of Medicine)

ax pharmaceutical corp - butylscopolamine bromide (unii: 0gh9jx37c8) (butylscopolamine - unii:2z3e1of81v) - butylscopolamine 49.5 g in 50 g

United States - English - NLM (National Library of Medicine)

pharmaderm a division of fougera pharmaceuticals inc. - methscopolamine bromide (unii: rtn51lk7wl) (methscopolamine - unii:vdr09vtq8u) - methscopolamine bromide 2.5 mg - adjunctive therapy for the treatment of peptic ulcer. methscopolamine bromide has not been shown to be effective in contributing to the healing of peptic ulcer, decreasing the rate of recurrence or preventing complications. glaucoma; obstructive uropathy (e.g., bladder neck obstruction due to prostatic hypertrophy); obstructive disease of the gastrointestinal tract (e.g., pyloroduodenal stenosis); paralytic ileus; intestinal atony of the elderly or debilitated patient; unstable cardiovascular status in acute hemorrhage; severe ulcerative colitis; toxic megacolon complicating ulcerative colitis; myasthenia gravis. pamine® 2.5 mg/pamine® forte 5 mg is contraindicated in patients who are hypersensitive to methscopolamine bromide or related drugs. not applicable.

United States - English - NLM (National Library of Medicine)

aace pharmaceuticals, inc. - methscopolamine bromide (unii: rtn51lk7wl) (methscopolamine - unii:vdr09vtq8u) - adjunctive therapy for the treatment of peptic ulcer. methscopolamine bromide has not been shown to be effective in contributing to the healing of peptic ulcer, decreasing the rate of recurrence or preventing complications. glaucoma; obstructive uropathy (e.g., bladder neck obstruction due to prostatic hypertrophy); obstructive disease of the gastrointestinal tract (e.g., pyloroduodenal stenosis); paralytic ileus; intestinal atony of the elderly or debilitated patient; unstable cardiovascular status in acute hemorrhage; severe ulcerative colitis; toxic megacolon complicating ulcerative colitis; myasthenia gravis. methscopolamine bromide tablets, 2.5 mg and 5 mg is contraindicated in patients who are hypersensitive to methscopolamine bromide or related drugs. not applicable.

United States - English - NLM (National Library of Medicine)

aarkish pharmaceuticals nj inc. - methscopolamine bromide (unii: rtn51lk7wl) (methscopolamine - unii:vdr09vtq8u) - adjunctive therapy for the treatment of peptic ulcer. methscopolamine bromide has not been shown to be effective in contributing to the healing of peptic ulcer, decreasing the rate of recurrence or preventing complications. glaucoma; obstructive uropathy (e.g., bladder neck obstruction due to prostatic hypertrophy); obstructive disease of the gastrointestinal tract (e.g., pyloroduodenal stenosis); paralytic ileus; intestinal atony of the elderly or debilitated patient; unstable cardiovascular status in acute hemorrhage; severe ulcerative colitis; toxic megacolon complicating ulcerative colitis; myasthenia gravis. methscopolamine bromide tablets, usp 2.5 mg and 5 mg is contraindicated in patients who are hypersensitive to methscopolamine bromide or related drugs. not applicable.